皮下过敏原免疫治疗真实世界持续性与依从性的系统综述
本系统综述检索多个数据库,纳入17篇真实世界研究(n=263,221例患者),评估皮下免疫治疗(SCIT)的持续性与依从性。14项研究报告持续性率范围16.0%至93.7%,7项报告依从性率范围15.1%至99%,多数研究报告率低于80%,作者认为真实世界SCIT持续性与依从性不佳,研究间测量与报告差异部分解释范围宽泛。
要点
- 真实世界SCIT持续性率范围16.0%至93.7%,依从性率范围15.1%至99%。
- 多数纳入研究报告的持续性与依从性率低于80%。
- 研究间测量与报告方法差异部分解释率值范围宽泛。
核心结论
- 真实世界SCIT持续性与依从性率不佳,多数纳入研究报告率低于80%,但范围宽泛,部分由研究间测量与报告依从性相关发现的差异解释。
研究设计与样本
- 系统综述,检索PubMed、Embase、Cochrane Library、Web of Science和Scopus中评估SCIT依从性的真实世界研究,由配对研究者独立审阅所有文章。
- 共检索到1596篇非重复摘要,最终纳入17篇文章(n=263,221例患者)。
- 文章质量先用改良纽卡斯尔-渥太华量表评估,再转换为医疗保健研究与质量局标准(好、中、差)。
主要发现
- 14项(82%)研究报告持续性率,范围16.0%至93.7%。
- 7项(41%)研究报告依从性率,范围15.1%至99%。
- 5项(29%)研究(n=416例患者)收集了停止SCIT原因的原数据,其中不便最常被提及。
- 所有研究为牛津证据等级2b,质量为好(n=10)至中(n=7)。
关键数值与推荐
- 本综述中持续性定义为开始SCIT后继续治疗且未失访,依从性定义为按照处方SCIT剂量、给药方案和疗程持续治疗。
局限性
- 研究间测量和报告依从性相关发现的差异部分解释了持续性与依从性率的宽泛范围。
- 未来SCIT依从性研究可能受益于遵循一致的持续性与依从性定义以及标准化报告指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given that subcutaneous immunotherapy (SCIT) adherence in the literature is often studied in closely monitored trials, few studies report real-world SCIT adherence. The purpose of this review is to assess SCIT adherence in real-world settings. METHODS: A literature search of PubMed, Embase, Cochrane Library, Web of Science, and Scopus for real-world studies examining SCIT adherence was performed. Paired investigators independently reviewed all articles. For this review, "persistence" was defined as continuing therapy and not being lost to follow-up after initiating SCIT, and "adherence" defined as persistence in accordance with prescribed SCIT dose, dosing schedule, and duration. Article quality was first assessed using a modified Newcastle-Ottawa scale and then converted to Agency for Healthcare Research and Quality standards (good, fair, and poor). RESULTS: The search yielded 1596 nonduplicate abstracts, from which 17 articles (n = 263,221 patients) met inclusion criteria. Fourteen (82%) studies reported persistence rates, ranging from 16.0% to 93.7%. Seven (41%) studies reported adherence rates, ranging from 15.1% to 99%. Five (29%) studies (n = 416 patients) collected original data on reasons for discontinuing SCIT, of which inconvenience was most cited. All studies were Oxford level of evidence 2b and of good (n = 10) to fair (n = 7) quality. CONCLUSION: Real-world SCIT persistence and adherence rates are poor, with the majority of included studies reporting rates <80%; however, they range widely, explained in part by inter-study differences in measuring and reporting adherence-related findings. Future studies on SCIT adherence may benefit from following concordant definitions of persistence and adherence in addition to standardized reporting metrics.
引用
- Park MJ, Kapoor S, Yi J, et al. Systematic review of real-world persistence and adherence in subcutaneous allergen immunotherapy. Int Forum Allergy Rhinol. 2022. PMID: 36083799. doi:10.1002/alr.23078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。